Market Closed -
Nasdaq
04:00:00 2024-05-13 pm EDT
|
5-day change
|
1st Jan Change
|
4.55
USD
|
-0.44%
|
|
+24.66%
|
+71.70%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,183
|
572.9
|
148.4
|
257.1
|
-
|
-
|
Enterprise Value (EV)
1 |
884
|
242.5
|
148.4
|
1.252
|
59.55
|
257.1
|
P/E ratio
|
-27.8
x
|
-9
x
|
-2.23
x
|
-4.46
x
|
-3.53
x
|
-3.45
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-24,759,117
x
|
-3,609,892
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
55,232
|
55,841
|
56,000
|
56,495
|
-
|
-
|
Reference price
2 |
21.41
|
10.26
|
2.650
|
4.550
|
4.550
|
4.550
|
Announcement Date
|
3/10/22
|
3/14/23
|
3/19/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-35.7
|
-67.19
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-35.83
|
-67.59
|
-78.19
|
-63.14
|
-77.54
|
-93.06
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-35.53
|
-63.31
|
-66.86
|
-66.88
|
-89.46
|
-97.1
|
Net income
1 |
-8.28
|
-35.53
|
-63.31
|
-66.86
|
-58.74
|
-77.08
|
-97.1
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.5216
|
-0.7700
|
-1.140
|
-1.190
|
-1.020
|
-1.290
|
-1.320
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/5/21
|
3/10/22
|
3/14/23
|
3/19/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-11.13
|
-13.37
|
-15.64
|
-19.19
|
-19.39
|
-21.65
|
-22.6
|
-18.82
|
-15.12
|
-14.4
|
-15.15
|
-16.09
|
-17.51
|
-21.68
|
-21.96
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-11.06
|
-13.26
|
-15
|
-17.7
|
-17.34
|
-19.29
|
-19.94
|
-15.79
|
-11.84
|
-11.1
|
-16.1
|
-18.27
|
-21.4
|
-21.68
|
-21.96
|
Net income
1 |
-11.06
|
-13.26
|
-15
|
-17.7
|
-17.34
|
-19.29
|
-19.94
|
-15.79
|
-11.84
|
-11.1
|
-14.4
|
-15.74
|
-17.5
|
-21.68
|
-21.96
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.2000
|
-0.2400
|
-0.2700
|
-0.3200
|
-0.3100
|
-0.3500
|
-0.3600
|
-0.2800
|
-0.2100
|
-0.2000
|
-0.2500
|
-0.2700
|
-0.3000
|
-0.3600
|
-0.3600
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/22
|
5/9/22
|
8/8/22
|
11/3/22
|
3/14/23
|
5/9/23
|
8/14/23
|
11/13/23
|
3/19/24
|
5/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
299
|
330
|
-
|
256
|
198
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/5/21
|
3/10/22
|
3/14/23
|
3/19/24
|
-
|
-
|
-
|
Last Close Price
4.55
USD Average target price
6.667
USD Spread / Average Target +46.52% Consensus |
1st Jan change
|
Capi.
|
---|
| +71.70% | 257M | | +26.37% | 48.16B | | -1.01% | 41.73B | | +42.44% | 41.03B | | -5.31% | 28.77B | | +9.34% | 25.59B | | -21.69% | 18.96B | | +6.23% | 12.92B | | +26.99% | 12.03B | | -3.38% | 11.77B |
Other Biotechnology & Medical Research
|